Ekachai Dumkliang

Dr. Ekachai Dumkliang

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 June 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
DBDina Bugybayeva
Dina Bugybayeva
EDEkachai Dumkliang
Ekachai Dumkliang
Veerupaxagouda PatilVeerupaxagouda Patil
Veerupaxagouda Patil
GYGanesh Yadagiri
Ganesh Yadagiri
RSRaksha Suresh
Raksha Suresh
Renukaradhya GourapuraRenukaradhya Gourapura
Renukaradhya Gourapura
This study focuses on the development and characterization of an intranasal vaccine platform using adjuvanted nanoparticulate delivery of swine influenza A virus (SwIAV). The vaccine employed whole inactivated H1N2 SwIAV as an antigen and STING-agonist ADU-S100 as an adjuvant, with both surface adsorbed or encapsulated in mannose–chitosan nanoparticles (mChit-NPs). Optimization of mChit-NPs included evaluating size, zeta potential, and cytotoxicity, with a 1:9 mass ratio of antigen to NP demonstrating high loading efficacy and non-cytotoxic properties suitable for intranasal vaccination. In a heterologous H1N1 pig challenge trial, the mChit-NP intranasal vaccine induced cross-reactive sIgA antibodies in the respiratory tract, surpassing those of a commercial SwIAV vaccine. The encapsulated mChit-NP vaccine induced high virus-specific neutralizing antibody and robust cellular immune responses, while the adsorbed vaccine elicited specific high IgG and hemagglutinin inhibition antibodies. Importantly, both the mChit-NP vaccines reduced challenge heterologous viral replication in the nasal cavity higher than commercial swine influenza vaccine. In summary, a novel intranasal mChit-NP vaccine platform activated both the arms of the immune system and is a significant advancement in swine influenza vaccine design, demonstrating its potential effectiveness for pig immunization.

7 November 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
JHJuan F Hernandez-Franco
Juan F Hernandez-Franco
GYGanesh Yadagiri
Ganesh Yadagiri
Veerupaxagouda PatilVeerupaxagouda Patil
Veerupaxagouda Patil
DBDina Bugybayeva
Dina Bugybayeva
SDSara Dolatyabi
Sara Dolatyabi
Harm HogenEschHarm HogenEsch
Harm HogenEsch
The development of cross-protective vaccines against the zoonotic swine influenza A virus (swIAV), a potential pandemic-causing agent, continues to be an urgent global health concern. Commercially available vaccines provide suboptimal cross-protection against circulating subtypes of swIAV, which can lead to worldwide economic losses and poor zoonosis deterrence. The limited efficacy of current swIAV vaccines demands innovative strategies for the development of next-generation vaccines. Considering that intramuscular injection is the standard route of vaccine administration in both human and veterinary medicine, the exploration of alternative strategies, such as intradermal vaccination, presents a promising avenue for vaccinology. This investigation demonstrates the first evaluation of a direct comparison between a commercially available multivalent swIAV vaccine and monovalent whole inactivated H1N2 swine influenza vaccine, delivered by intradermal, intranasal, and intramuscular routes. The monovalent vaccines were adjuvanted with NanoST, a cationic phytoglycogen-based nanoparticle that is combined with the STING agonist ADU-S100. Upon heterologous challenge, intradermal vaccination generated a stronger cross-reactive nasal and serum antibody response in pigs compared with intranasal and intramuscular vaccination. Antibodies induced by intradermal immunization also had higher avidity compared with the other routes of vaccination. Bone marrow from intradermally and intramuscularly immunized pigs had both IgG and IgA virus-specific antibody-secreting cells. These studies reveal that NanoST is a promising adjuvant system for the intradermal administration of STING-targeted influenza vaccines.

19 January 2024 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
EDEkachai Dumkliang
Ekachai Dumkliang
PSPhuvamin Suriyaamporn
Phuvamin Suriyaamporn
PPPrasopchai Patrojanasophon
Prasopchai Patrojanasophon
TNTanasait Ngawhirunpat
Tanasait Ngawhirunpat
TRTheerasak Rojanarata
Theerasak Rojanarata
BPBoonnada Pamornpathomkul
Boonnada Pamornpathomkul

6 April 2024 in Indian Journal of Otolaryngology and Head & Neck Surgery
Verified
Journal Article
Open access
PDF file
ADArunrat Dumkliang
Arunrat Dumkliang
APAmarawan Pentrakan
Amarawan Pentrakan
EDEkachai Dumkliang
Ekachai Dumkliang
[This corrects the article DOI: 10.1007/s12070-024-04560-8.].

24 February 2024 in Indian Journal of Otolaryngology and Head & Neck Surgery
Verified
Journal Article
Closed access
PDF file
ADArunrat Dumkliang
Arunrat Dumkliang
APAmarawan Pentrakan
Amarawan Pentrakan
EDEkachai Dumkliang
Ekachai Dumkliang